Unilife Corporation Donates First Shipment of Unitract(TM) Safety Syringes to Haitian Relief Efforts

Tuesday, February 23, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

LEWISBERRY, Pa., Feb. 22 Unilife Corporation (Company) (Nasdaq: UNIS, ASX: UNS), today announced that it has donated its first shipment of Unitract(TM) 1mL safety syringes to Doctors Without Borders to support ongoing relief efforts in Haiti.

"Unilife designs, manufactures and supplies best-in-class safety syringes that can help save and enhance lives. As such, we cannot think of a more suitable way to mark the start of international distribution of our Unitract(TM) 1mL safety syringes than to send our first shipment to Haiti in support of ongoing relief efforts," stated Alan Shortall, CEO of Unilife. "We are pleased that we could make a contribution to the relief effort considering the significant shortage of medical supplies in Haiti. We hope to make additional contributions in the near future."

The Unitract(TM) range of 1mL syringes is the world's first and only known syringe that allows operators to control the speed of automatic needle retraction directly from the patient's body into the barrel of the syringe where it is locked in place. The products are well positioned to help prevent the transmission of blood-borne diseases such as HIV and hepatitis C via aerosol dispersal, needlestick injuries and syringe reuse. Primary target markets of the products include healthcare facilities, pharmaceutical companies and patients who self-administer prescription medication.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

Unilife's main product is the Unifill(TM) ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with injectable drugs and vaccines. The Company has a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill(TM) syringe and is funding an industrialization program for the product. In addition, Unilife has retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our future reports which we will file with the Securities and Exchange Commission.

Investor Contacts Investor Contacts (US): (Australia) Todd Fromer / Garth Russell Stuart Fine Jeff Carter KCSA Strategic Communications Carpe DM Inc Unilife Corporation Phone Phone Phone + 1 212-682-6300 + 1 908 469 1788 + 61 2 8346 6500

SOURCE Unilife Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store